ESMERALDA BARRAGAN: Open Payments
NPI 1417426842 · SPRING, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$465 in 24 payments from 9 companies in 2025. Trend: 2023 $588 · 2024 $833 · 2025 $465
Food & beverage: $465
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $122 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $107 |
| AstraZeneca Pharmaceuticals LP | 4 | $83 |
| Lilly USA, LLC | 4 | $67 |
| Exact Sciences Corporation | 1 | $26 |
| Abbott Laboratories | 1 | $18 |
| Cranial Technologies, Inc | 1 | $14 |
| SHIELD THERAPEUTICS INC | 1 | $14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: Kerendia, Ozempic, Rybelsus, FARXIGA, MOUNJARO, Cologuard Collection Kit, JARDIANCE, FREESTYLE LIBRE 3.
Industry payments across TX — which companies pay providers there.
